Pharmafile Logo
Pharmafocus logo
Advanced Search

EMG appoints two new senior members

April 4, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing EMG, Matthew Speers, Steve Turley, UCB

A new chair and vice-chair have been appointed to lead the European Medicines Group (EMG).   EMG is the voice of …

Appointment

Glyn Edwards appointed as chief executive of Summit

April 4, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Glyn Edwards, summit

Summit, a UK drug discovery company, has appointed Glyn Edwards as its new chief executive. Edwards will take up the …

Appointment

EMA creates new conflict of interest rules

April 4, 2012
Sales and Marketing EMA, Lonngren, conflict of interest

The European Medicines Agency has introduced new rules to tighten up conflicts of interest, and have less reliance on pharma …

News

New Europe-wide approach for the classification of commercially confidential information and personal data in MAAs

April 3, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The Heads of Medicines Agencies(HMA) and the European Medicines Agency (EMA) have adopted a joint guidance document, providing a consistent …

News
Press release

Catalent Extends Development and Analytical Solutions Capabilities in Swindon, UK

April 3, 2012
Research and Development

Somerset, NJ – March 22, 2012 — Catalent Pharma Solutions today announces the completion of new Development and Analytical Solutions’ …

News
Press release
Bayer image

Bayer cancer drug meets Phase III goal

April 3, 2012
Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …

News

Life appoints new digital developer

April 3, 2012
Business Services, Medical Communications, Sales and Marketing Life, Nick Douglas

Life Healthcare Communications has created a new digital developer role, continuing the growth of its digital department.  The firm has …

Appointment

Standardised equipment and centralised spirometry for optimal data quality

April 3, 2012
Research and Development

IntroductionWhen developing the treatments for asthma and COPD, pharmaceutical companies utilise pulmonary function testing (PFT) to determine each compound’s efficacy. …

Feature
Thought Leadership

Considerations with dual site production

April 3, 2012
Research and Development

There are generally two options available when looking to expand storage capacity – build to develop existing facilities or select …

Feature
Thought Leadership

Novasep expands in China, raises €40m for investments

April 3, 2012
Manufacturing and Production China, Novasep, Shanghai, manufacturing

French processing equipment supplier Novasep has opened a new facility in China to meet what it says is increasing demand …

News

Pharma manufacturing news in brief

April 3, 2012
Manufacturing and Production Gerresheimer and Foster Wheeler, Pharmax, Sigma-Aldrich

Pharmax starts building Dubai plant, Brazil tightens gelatin controls, plus updates from Sigma-Aldrich, Gerresheimer and Foster Wheeler.

News

Michael Cola resigns from Shire

April 3, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Michael Cola, Shire

Michael Cola has resigned as the president of Shire Specialty Pharmaceuticals after seven years at the firm.  “On behalf of …

Appointment
Halaven image

NICE rejects Halaven for breast cancer

April 3, 2012
Sales and Marketing Eisai, Halaven, NICE, breast cancer

NICE has rejected Eisai’s novel breast cancer drug Halaven, due to concerns over its safety and costs.  In its final …

News

Moving Towards a Risk-Based approach to Clinical Trial Management

April 3, 2012
Research and Development

Clinical trials need to be managed to rigorous standards in order to secure the quality and integrity of every aspect …

Feature
Thought Leadership

Universal WorldEvents Marks Anniversary with Increase in Events

April 2, 2012
Sales and Marketing

Universal WorldEvents has marked its first anniversary by revealing a significant increase in the number of events organised by the …

News
Press release

Novartis to construct pharma plant in Turkey

April 2, 2012
Manufacturing and Production Novartis, Turkey, manufacturing

Novartis has selected Turkey as its headquarters for central Asia, the Middle East and Africa and intends to set up …

News

AstraZeneca wins fresh US victory with Seroquel XR

April 2, 2012
Sales and Marketing AZ, AstraZeneca, FDA, Seroquel XR

AstraZeneca is celebrating a US court verdict in its ongoing battle for intellectual property over the extended release version of …

News

Piramal opens ADC plant in Scotland

April 2, 2012
Manufacturing and Production ADC, Abbott, Piramel

India’s Piramal Healthcare has officially opened a new production unit to make antibody-drug conjugates at its facility in Grangemouth, Scotland. …

News
Roche image

Roche to submit Herceptin successor to regulators

April 2, 2012
Research and Development, Sales and Marketing GSK, Herceptin, Roche, Xeloda

Roche has said it will submit its new breast cancer drug trastuzumab for regulatory review in the US and Europe …

News
Roche image

Roche raises Illumina bid to $6.7 billion

April 2, 2012
Sales and Marketing

Roche has increased its takeover bid for Illumina, with the offer now valuing the company at $6.7 billion.The firm makes …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026